RxDoctor Payments Data

Lauri An, MD

Family Medicine · Los Angeles, CANPI 1134168891

Payments from drug & device makers

$3,928in general payments, 2019–2025

Across 177 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$863
  • AbbVie$860
  • Amgen$792
  • Ardelyx, Inc.$220
  • Bayer$155
  • AstraZeneca$150
  • plus $887 from 13 others

What the payments were for

  • Food & beverage$3,928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,928 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$32,234
Medicare patients
64
Services billed
608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin267$194,672
CreonLipase/Protease/Amylase127$150,263
TradjentaLinagliptin84$56,435
JanuviaSitagliptin Phosphate70$51,883
LinzessLinaclotide73$48,854
VascepaIcosapent Ethyl126$47,049
KerendiaFinerenone59$44,930
TrulicityDulaglutide33$31,759
JanumetSitagliptin Phos/Metformin Hcl47$30,791
FarxigaDapagliflozin Propanediol29$28,075
Jentadueto XrLinagliptin/Metformin Hcl42$26,001
JentaduetoLinagliptin/Metformin Hcl43$25,223
ZenpepLipase/Protease/Amylase14$17,249
Janumet XrSitagliptin Phos/Metformin Hcl23$17,200
GlyxambiEmpagliflozin/Linagliptin24$16,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr, Jentadueto, Glyxambi$88$319,167460 claims
AbbVieCreon, Linzess, Restasis, Namzaric$860$223,079231 claims
BayerKerendia$155$44,93059 claims
Lilly USA, LLCTrulicity$107$31,75933 claims
AstraZenecaFarxiga$150$28,07529 claims
Aimmune Therapeutics, Inc.Zenpep$75$17,24914 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$31$9,69011 claims
GSKArexvy$26$5,84420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →